PUBLIC COMPANY
save$WVEWave Life Sciences Ltd.
$WVE3.4850+1.01%Singapore, SGupdated 23d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
- phase2A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
- phase1A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)
- phase2Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy
- phase2Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
- phase2Study of WVE-003 in Patients With Huntington's Disease
- phase2Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
- phase2Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
🐶 Hiring Signal
News
- Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlightThe FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…biospace · 2d ago
- ObesityWeek 2026: Wave outlines case for body composition–based trial designAcross three cohorts in Wave Life Sciences’ mid-stage trial of WVE-007, higher baseline body mass index and excessive body fat have been associated with a more pronounced effect, Rodman & Renshaw s…biospace · 4d ago
- Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…biospace · 7d ago
- Roche extends China deal streak with $1B pact for RNAi obesity drugAn alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on medicines that can lower levels of “visceral” fat.biopharma_dive · 1mo ago
- Reusing data could cut R&D costs and greatly increase gene editing’s reach: ARMLeveraging recently proposed regulatory flexibilities, the gene-editing sector is working to cut R&D costs and unlock indications that were previously economically unviable, according to a new play…biospace · 1mo ago
- Lilly, Foghorn part ways; Wave’s FDA-approved plansThe pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.biopharma_dive · 1mo ago
- GSK continues to stock up on Wave's RNA drugs with liver-focused programGSK is paying Wave Life Sciences $12 million upfront to take ownership of a hepatic program arising from the companies’ long-running collaboration.fiercebiotech · 1mo ago
- Roche drops muscle-sparing obesity antibody after flunked interim analysisRoche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a phase 2 study.fiercebiotech · 1mo ago
- Chutes & Ladders—Travere chief makes way for former Amicus CEOTravere Therapeutics CEO Eric Dube, Ph.D., is stepping down after overseeing the launch of the rare kidney disease drug Filspari.fiercebiotech · 1mo ago
- Moonwalk reloads with $70M and new RNAi prospects for obesityThe California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.biopharma_dive · 2mo ago
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that